Pegfilgrastim
| Systematic (IUPAC) name | |
|---|---|
|
N-(3-Hydroxypropyl)Methionylcolony-stimulating Factor (human), 1-Ether with .Alpha.-Methyl-.Omega.-Hydroxypoly(Oxyethylene) | |
| Clinical data | |
| Trade names | originally Neulasta, other brand names worldwide[1] |
| AHFS/Drugs.com | monograph |
| MedlinePlus | a607058 |
| Pregnancy category |
|
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Biological half-life | 15–80 hrs |
| Identifiers | |
| CAS Number |
208265-92-3  |
| ATC code | L03AA13 (WHO) |
| IUPHAR/BPS | 6969 |
| DrugBank |
DB00019 |
| ChemSpider | none |
| UNII |
3A58010674 |
| KEGG |
D06889 |
| ChEMBL |
CHEMBL1201568  |
| Chemical data | |
| Formula | C845H1343N223O243S9 + PEG |
| Molar mass | 39,000 g/mol |
| (what is this?) (verify) | |
Pegfilgrastim is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (GCSF) analog filgrastim. It serves to stimulate the level of white blood cells (neutrophils).[2]
Pegfilgrastim treatment can be used to stimulate bone marrow to produce more neutrophils to fight infection in patients undergoing chemotherapy.[3]
Pegfilgrastim has a human half-life of 15 to 80 hours, much longer than the parent filgrastim (3–4 hours).[4][3]
See also
References
- ↑ Drugs.com International brand names for pegfilgrastim Page accessed April 1, 2016
- ↑ Walsh, G, Spada, S. "Epogen/Procrit" in: Directory of approved biopharmaceutical products. CRC Press, 2005, pp. 136–137.
- 1 2 Drugs.com: Pegfilgrastim
- ↑ Ho, R.J.Y., Gibaldi, M. Biotechnology and biopharmaceuticals: transforming proteins and genes into drugs Wiley-IEEE, 2003, p. 139, 158.
External links
- Neulasta
- Neulasta full prescribing information
- Neulasta Onpro kit Healthcare Provider Instructions for Use
| ||||||||||||||||||||||||||||||
This article is issued from Wikipedia - version of the Saturday, April 02, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.